Active — Not RecruitingNot Applicable

Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer

United States152 participantsStarted 2018-09-11

Plain-language summary

This trial studies how well self-hypnosis works in enhancing recovery after surgery in patients with gynecologic cancer. A guided relaxation method called self-hypnosis may help affect how patients feel pain and symptoms after surgery.

Who can participate

Age range

18 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Undergoing an exploratory laparotomy for suspected gynecologic cancer, which includes metastatic disease from neoplasia originating in other organs * Planned participation in the Gynecologic Enhanced Recovery Pathway * Patient must be able to read, understand, and speak English * Consents to being part of a randomized study * Patient has physical and mental capabilities to take part in study Exclusion Criteria: * Sensitivity to amide-type local anesthetics * Patients on long-acting opioid medications, or scheduled (four or more times a day for seven or more days) short-acting opioid medications within the last 30 days * Emergency surgery of any type that does not allow for proper time for protocol review by the patient * Surgery that involves known/anticipated resection of anterior abdominal wall with plastic surgery reconstruction * Patients undergoing known/anticipated anterior abdominal wall hernia repairs * Patients undergoing pelvic exenteration * Patients with known major psychiatric disease * Patients with hearing impairment such that they are unable to hear the intervention

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Feasibility of participating in pre-operative self-hypnosis

Timeframe: Up to 1 day

Patients' perception of post-surgical pain

Timeframe: Post-operative day 1 (POD1)

Trial details

NCT IDNCT04266886

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12-31

View on ClinicalTrials.gov More Malignant Female Reproductive System Neoplasm trials